WB | 咨询技术 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
FCM | 1/200 - 1/400 | Human,Mouse,Rat |
Elisa | 1/10000 | Human,Mouse,Rat |
Aliases | IGA; MB-1 |
Entrez GeneID | 973 |
clone | 4A10D12 |
WB Predicted band size | 25kDa |
Host/Isotype | Mouse IgG2b |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Purified recombinant fragment of human CD79A (AA: extra(33-143)) expressed in E. Coli. |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD79A抗体的3篇代表性文献,按文献名称、作者和摘要内容简要概括:
---
1. **文献名称**:*CD79a: A Review of Its Role in B-Cell Development and Malignancies*
**作者**:van der Burg, M., et al.
**摘要**:该综述总结了CD79a作为B细胞受体(BCR)信号复合物的关键成分,在B细胞发育和功能中的作用。文章重点讨论了CD79a抗体在诊断B细胞恶性肿瘤(如弥漫大B细胞淋巴瘤)中的应用,并分析了其作为免疫组化标记物的敏感性和特异性。
2. **文献名称**:*Targeting CD79A in B-Cell Receptor Signaling: Insights from Monoclonal Antibody Development*
**作者**:Dörner, T., et al.
**摘要**:研究报道了一种新型抗CD79A单克隆抗体的开发,用于抑制过度激活的BCR信号通路。实验表明,该抗体能有效阻断B细胞异常活化,为自身免疫疾病(如系统性红斑狼疮)的靶向治疗提供了潜在策略。
3. **文献名称**:*CD79A Mutations and Altered B-Cell Signaling in Chronic Lymphocytic Leukemia*
**作者**:Davis, R.E., et al.
**摘要**:通过CD79A抗体检测慢性淋巴细胞白血病(CLL)患者的样本,研究发现CD79A的突变导致BCR信号传导异常,揭示了其在疾病进展中的作用,并提出针对该通路的治疗可能改善患者预后。
---
如需更详细文献信息(期刊、年份等),可进一步补充关键词或限定条件。
CD79a, a key component of the B-cell receptor (BCR) complex, is encoded by the CD79A gene and pairs with CD79b to form a heterodimer essential for BCR surface expression and signal transduction. As a transmembrane immunoglobulin, CD79a contains an immunoreceptor tyrosine-based activation motif (ITAM) that recruits kinases like Syk upon antigen binding, initiating downstream signaling critical for B-cell development, activation, and differentiation.
CD79a antibodies are valuable tools in research and diagnostics, specifically targeting the invariant CD79a protein expressed exclusively on B-cells. These antibodies enable the identification of B-cell lineages in tissues and blood, aiding in the classification of B-cell malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Unlike markers like CD20 or CD19. CD79a retains expression in certain immature B-cell neoplasms and plasma cells, enhancing diagnostic accuracy.
Therapeutically, CD79a has emerged as a potential target for antibody-drug conjugates (ADCs) or bispecific antibodies designed to direct immune cells against malignant B-cells. Recent studies also explore its role in autoimmune diseases, where aberrant BCR signaling contributes to pathology. However, targeting CD79a presents challenges due to its broad expression on healthy B-cells, necessitating precise engineering to balance efficacy and toxicity. Ongoing research continues to refine CD79a antibody applications, bridging gaps in understanding B-cell biology and improving clinical outcomes.
×